Serum netrin-1 and netrin receptor levels in fibromyalgia and osteoarthritis

dc.contributor.authorKohle, Alparslan
dc.contributor.authorGulkesen, Arif
dc.contributor.authorKaratas, Tuba Kaya
dc.contributor.authorAkgol, Gurkan
dc.contributor.authorKaratas, Ahmet
dc.contributor.authorIlhan, Necip
dc.contributor.authorKoca, Suleyman Serdar
dc.date.accessioned2026-08-12T17:20:32Z
dc.date.issued2022
dc.departmentFırat Üniversitesi
dc.description.abstractObjectives: This study aims to define serum levels of netrin-1 and netrin receptors in patients with fibromyalgia (FM) and osteoarthritis (OA). Patients and methods: This cross-sectional study was conducted with a total of 150 female participants (mean age: 47.2 +/- 16.1 years; range, 18 to 89 years) at F??rat University between June 2016 and December 2016. The participants were evaluated in three groups: the FM group with 50 patients, the OA group with 50 patients, and the control group, which included 50 healthy volunteers. Netrin-1, netrin receptors (DCC, UNC5B, and UNC5D), interleukin (IL)-6, IL-10, and IL-17 levels were analyzed by the enzyme-linked immunosorbent assay from the serum samples of the participants. Results: The level of serum netrin-1 was significantly lower in the FM group than in the control and OA groups (p<0.01 and p<0.001, respectively). However, the difference between patients with OA and healthy controls in terms of netrin-1 was not statistically significant (p>0.05). In addition, serum levels of netrin receptors and cytokines in the FM group were similar to the control group (p>0.05). However, serum DCC, UNC5D, IL-6, and IL-10 levels were higher in the OA group compared to the control group (p<0.001, p<0.05, p<0.01, and p<0.001, respectively). Conclusion: Serum netrin-1 level is suppressed in FM, which suggests that netrin-1 is influential in FM pathogenesis.
dc.description.sponsorshipTurkish Society for Rheumatology
dc.description.sponsorshipThis study was supported by the Turkish Society for Rheumatology.
dc.identifier.doi10.5606/tftrd.2022.8114
dc.identifier.endpage245
dc.identifier.issn2587-1250
dc.identifier.issue2
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.pmid35989959
dc.identifier.scopus2-s2.0-85139733724
dc.identifier.scopusqualityQ2
dc.identifier.startpage238
dc.identifier.trdizinid1176145
dc.identifier.urihttps://doi.org/10.5606/tftrd.2022.8114
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1176145
dc.identifier.urihttps://hdl.handle.net/11508/53599
dc.identifier.volume68
dc.identifier.wosWOS:000808471800001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBaycinar Medical Publ-Baycinar Tibbi Yayincilik
dc.relation.ispartofTurkish Journal of Physical Medicine and Rehabilitation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectCytokine
dc.subjectfibromyalgia
dc.subjectnetrin-1
dc.subjectosteoarthritis
dc.titleSerum netrin-1 and netrin receptor levels in fibromyalgia and osteoarthritis
dc.typeArticle

Dosyalar